Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Issued
Ratios

Ligand Pharmaceuticals (LGNDZ) Accumulated Depreciation & Amortization (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Accumulated Depreciation & Amortization for 16 consecutive years, with $33.8 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization fell 4.15% to $33.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.8 million through Dec 2025, down 4.15% year-over-year, with the annual reading at $33.8 million for FY2025, 4.15% down from the prior year.
  • Accumulated Depreciation & Amortization hit $33.8 million in Q4 2025 for Ligand Pharmaceuticals, down from $35.2 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $51.5 million in Q4 2022 to a low of $33.8 million in Q4 2025.
  • Historically, Accumulated Depreciation & Amortization has averaged $41.6 million across 5 years, with a median of $36.5 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 98.79% in 2021 and later decreased 29.13% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $51.1 million in 2021, then rose by 0.91% to $51.5 million in 2022, then decreased by 29.13% to $36.5 million in 2023, then dropped by 3.51% to $35.2 million in 2024, then decreased by 4.15% to $33.8 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for LGNDZ at $33.8 million in Q4 2025, $35.2 million in Q4 2024, and $36.5 million in Q4 2023.